Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Financings Routine −

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Financing Finalized at Discount as Dilution Concerns Weigh on Stock

By The Northwire Desk — AI Analysis May 19, 2026 · 07:00 MDNA · 0.54 MEDICENNA THERAPEUTICS CORP. J
Executive Summary
  • Medicenna Therapeutics has finalized terms for a public offering of units priced at $0.50 per unit.
  • Each unit consists of one common share and one-half warrant with an exercise price of $0.65 expiring in three years.
  • The offering is underwritten by Bloom Burton Securities Inc., expected to close around May 27, 2026.
  • Proceeds are designated for clinical/regulatory development of MDNA11 and MDNA113, working capital, and general corporate purposes.
  • This follows the launch announcement on May 13, 2026, which was priced as a best-efforts marketed offering.
Material Impact
  • The financing is dilutive to existing shareholders given the $0.50 offering price against recent trading levels near $0.60-$0.66 prior to finalization.
  • While essential for extending cash runway beyond Q3 2026, the discount pricing signals market pressure and lack of premium valuation support.
  • The terms are consistent with previous announcements (May 13), making this a follow-up event rather than new information.
  • Dilution risk is immediate upon closing, likely suppressing stock price momentum despite clinical progress.
MDNA · Price
Company Overview
  • Medicenna Therapeutics develops immunotherapy assets focused on IL-2 Superkines and bifunctional proteins.
  • Flagship asset MDNA11 is a long-acting "beta-enhanced not-alpha" IL-2 Superkine currently in Phase 1/2 ABILITY-1 trial for advanced solid tumors.
  • MDNA113 is a first-in-class tumor-anchored anti-PD-1 x IL-2 bifunctional protein advancing toward IND submission.
  • Bizaxofusp (MDNA55) targets recurrent glioblastoma with Phase 2b data showing improved overall survival compared to standard care.
Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J

Jun 26, 2026 · 08:45

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Earnings Jun 11, 2026 · 07:00

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

M&A / Property Jun 03, 2026 · 07:00

ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

Other May 28, 2026 · 09:10

Medicenna Secures $12.4M Lifeline Amidst Dilution Concerns and Clinical Milestones

Financings May 22, 2026 · 07:00

Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

Financings May 13, 2026 · 16:01

Cash Runway Expiry Triggers Dilutive Financing Despite Clinical Milestones

Financings